OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

OptimizeRx (NASDAQ:OPRX) issued its earnings results on Thursday. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.18, Zacks reports. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. The company had revenue of $32.24 million for the quarter, compared to analysts’ expectations of $30.92 million.

Here are the key takeaways from OptimizeRx’s conference call:

• Strong FY2025 results: Q4 revenue was $32.2M and adjusted EBITDA $12M, with full-year revenue $109.4M, adjusted EBITDA $24.3M, Rule of 40 performance, >20% adjusted EBITDA margin, and nearly $19M in operating free cash flow.
• Conservative 2026 guidance: Management lowered 2026 revenue to $109M–$114M and adjusted EBITDA to $21M–$25M, citing softness from a market shift away from managed services and MFN-driven client conservatism that shortened contract durations.
• Capital allocation and balance sheet actions: Year-end cash/short-term investments rose to $23.4M after $8M of debt paydown, the board authorized a $10M share repurchase, and management plans to prioritize debt reduction while opportunistically buying back stock.
• Growth & product momentum: Management highlighted DAAP/DAAP subscription conversion near a ~10% exit run-rate, a 116% net revenue retention rate, expanding wins with mid-tier and med-tech clients, and views AI as a potential tailwind reallocating spend toward execution where OptimizeRx competes.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded down $1.24 during trading on Friday, reaching $6.29. 597,732 shares of the company traded hands, compared to its average volume of 369,775. The firm has a market capitalization of $117.25 million, a PE ratio of 19.67 and a beta of 1.20. OptimizeRx has a 52 week low of $3.99 and a 52 week high of $22.25. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The company’s 50 day moving average is $10.63 and its two-hundred day moving average is $14.80.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on OPRX. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Stephens reduced their price objective on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday. Stifel Nicolaus dropped their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and an average target price of $18.50.

Key Headlines Impacting OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results and earnings beat: OptimizeRx reported quarterly results that topped analyst expectations (company-raised EPS vs. consensus) and highlighted solid revenue growth — the beat is driving early upside. GlobeNewswire press release
• Positive Sentiment: Board-approved $10M buyback: The company authorized up to $10.0 million in repurchases (≈6.8% of shares), signaling management believes the stock is undervalued — this typically supports the share price. RTT News
• Positive Sentiment: Conference call & analyst coverage highlighted growth drivers: Management discussed strategic initiatives and revenue growth drivers on the call, which investors often view positively for forward visibility. Yahoo Finance call highlights
• Neutral Sentiment: Full transcripts and materials posted: Earnings release, call transcript and slide materials are available for review (useful for investors doing due diligence). Seeking Alpha transcript
• Neutral Sentiment: Temporary trading halt (LULD pause): Trading was halted intraday due to a Limit Up-Limit Down (LULD) pause — a procedural pause tied to rapid price movement, not company-specific regulatory action. Exchange halt notice
• Negative Sentiment: FY‑2026 revenue guidance below consensus: Management guided revenue to $109M–$114M for FY‑2026 versus a consensus near $122.1M, a notable downward gap that is likely the primary reason investors are cautious despite the quarter’s beat. Seeking Alpha guidance story

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in OptimizeRx in the 2nd quarter valued at about $44,000. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. Worth Venture Partners LLC bought a new position in OptimizeRx in the third quarter valued at approximately $220,000. ExodusPoint Capital Management LP acquired a new position in OptimizeRx during the fourth quarter valued at approximately $150,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in OptimizeRx during the fourth quarter worth $158,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx declared that its Board of Directors has authorized a stock buyback plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.